Commercial Space Company Risk / Opportunity Ranking

Thesis: Northwood Space has one of the cleaner opportunity setups in this screen because the reviewed sources membership rationale says it raised $100 million in a notable space startup funding deal, which can matter over a 1 year+ horizon by extending development and commercialization runway.

Why now: The rationale references article: and states Northwood Space raised $100 million in a notable spacetech funding deal; that size of financing is plausibly durable over a 1 year+ horizon, though recency cannot be fully validated from the absent article body.

Caveats: No representative article or provided in the visible evidence body. No direct evidence after recent evidence window are exposed despite the positive rationale. Funding alone does not prove technical or commercial execution.

Thesis: Orbital has a credible long-horizon opportunity signal because it was reported as having closed funding to verify a space-based data center concept, which supports continued development of an AI satellite constellation concept as of April 14, 2026.

Why now: The usable evidence is recent within the 90-day recent evidence window: an April 14, 2026 article said Orbital got funded by Andreessen Horowitz to verify its space-based data center concept, which is relevant to a 1 year+ horizon because financing can support technology proof and strategic positioning

Caveats: Evidence is supporting article context/weak context rather than direct positive events. No reviewed sources evidence of customers, revenue, launch schedule, or technical milestone completion. Same article appears in multiple weak-context rows and should not be treated as independent confirmation.

Thesis: Redwire has the strongest opportunity evidence in this screen because the reviewed sources includes dated within the recent evidence window article context for both a June 4, 2026 contract from Astrobiome Space to launch the inaugural mission in the world’s first commercial space greenhouse on the ISS and an April 8, 2026 article listing Redwire among the Andromeda awardees. Together, these point to activity across both commercial in-space applications and national-security space programs over a 1 year+ horizon.

Why now: The why-now case is the best in the set: a published June 4, 2026 article says Redwire was awarded a contract from Astrobiome Space for the inaugural flight of its commercial space greenhouse on the ISS. Earlier, on April 8, 2026, Defense Daily reported Redwire among companies awarded more than $1.8 billion total under the Andromeda SDA contracts. Those dated items suggest current business momentum that could matter over a 1 year+ horizon.

Caveats: Evidence is weak-context/supporting article context, not direct positive events. The standard-journal article carrying similar June 4, 2026 text is undated in the reviewed sources and should not be treated as independent confirmation. No material adverse evidence is available, but absence of negative evidence is not proof of low risk.

Thesis: Scout Space has credible growth-stage opportunity from a newly announced Series A financing and stated manufacturing expansion, which could support scaling of SDA sensors and software over a 1 year+ horizon.

Why now: A dated May 6, 2026 article says Scout raised up to $18 million Series A and will use the capital for mission execution and expansion of manufacturing capabilities, creating a current capacity-building milestone for the next year, May 6, 2026).

Caveats: Most available support is weak context/supporting article context rather than direct positive events. Blue Origin partnership articles are from 2025 and were outside the 90-day recent evidence window, so they should not drive recency-based ranking

Thesis: SES has the strongest current opportunity setup in this screen because within the recent evidence window dated evidence says SES was selected as a prime contractor in the U.S. Space Force Protected Tactical Satcom-Global program, with a combined $437.7 million award for SES and Viasat to each build and operate a satellite. That indicates current government program relevance with potential multiyear strategic value.

Why now: The key evidence is recent and within the recent evidence window: a June 11, 2026 SpaceNews article says SES was selected last month as a prime contractor under the PTS-G program, with K2 Space providing SES's satellite platform

Caveats: Reviewed evidence is still supporting article context rather than a direct company filing. The Impulse transportation agreement is older and outside the 90-day recent evidence window.

Thesis: Starcloud is the strongest opportunity candidate in this screen because recent dated article context indicates capital raised and incremental network buildout steps for its orbital data center concept. A March 30, 2026 article says Starcloud raised $170 million at a $1.1 billion valuation. A later May 26, 2026 article says Starcloud announced a contract for more than 50 Starlink Mini Lasers to equip at least 25 satellites and use Starlink as a global data-relay network. A June 10, 2026 article further describes Starcloud as having raised about $200 million to date for a proposed constellation of 88,000 orbital data centers.

Why now: Within the 90-day recent evidence window, Starcloud has the clearest sequence of dated business-state updates: funding on March 30, 2026, network-equipment contract on May 26, 2026, and additional context on capital raised and market positioning on June 10, 2026, For a 1 year+ horizon, that sequence supports an active buildout story even though evidence quality is not fully direct.

Caveats: All usable evidence is supporting article context; the reviewed sources provide no direct positive or negative dated event/facts. Repeated Starcloud claims across articles are not independent confirmation under the evidence standard. Opportunity and risk both remain dependent on future execution over a long horizon.

Thesis: Synspective has the strongest opportunity evidence in this screen because multiple within the recent evidence window dated article-context items point to operational and strategic scaling: a May 1, 2026 article says Rocket Lab launched Synspective's ninth StriX SAR satellite, improving its ability to deliver persistent Earth observation capabilities; a June 3, 2026 press release says Synspective and KSAT expanded their strategic alliance to support constellation expansion; and a May 21, 2026 company page describes an operating fleet, SAR data sales, and solution services for government and commercial customers

Why now: The recency stack is favorable for a 1 year+ thesis: May 1, 2026 launch progress, May 21, 2026 operating-profile context, and June 3, 2026 alliance expansion together suggest that constellation buildout and service-capability scaling were active in the most recent recent evidence window period

Caveats: Evidence is supporting article context and mostly neutral-polarity in reviewed sources structure, not direct dated event/facts. Two key supportive items are company-sourced pages/press releases. No retained adverse evidence exists, but absence of bad news is not proof of low risk.

Thesis: Recent article context says UNASTELLA raised $24 million to develop its own launch vehicles and engines, a meaningful capital-and-capability milestone for a rocket startup with potential multi-year product development relevance.

Why now: The funding context is dated June 1, 2026 and sits well within the 90-day recent evidence window, making it recent enough to support a 1 year+ development runway thesis. Source date: June 1, 2026

Caveats: Evidence is from a LinkedIn space briefing and is supporting article context only. No direct product milestone, customer, or contract evidence is available.

Thesis: Vast Space has the strongest opportunity profile in this screen because within the recent evidence window dated article context indicates a strategic expansion from commercial space stations into satellite manufacturing through a new high-power satellite bus line, with one article saying the new line targets communications, Earth observation, national security, and orbital data center constellations, and another saying Vast already has a customer. This product-line expansion can matter over a 1 year+ horizon if it broadens revenue sources beyond stations, May 19, 2026, May 19, 2026).

Why now: The timing case is stronger than peers because the product expansion articles are dated May 19, 2026 and May 20, 2026, within the 90-day recent evidence window, and represent a potentially durable strategic change: moving into satellite buses rather than remaining only a station developer, May 19, 2026, May 20, 2026).

Caveats: Retained evidence is weak context supporting article context; there are no direct positive event/facts available. The March 2026 financing articles are outside the 90-day recent evidence window and cannot be primary support, even though they appear in representative articles. Several retained rows summarize the same basic product announcement and should not be treated as independent confirmation.

Thesis: Voyager Space has the strongest reviewed sources-supported opportunity because within the recent evidence window it has dated evidence of a $16.5 million DARPA Phase 2 contract and dated company context showing electric propulsion capabilities for satellite constellations and broader space technologies, supporting a durable defense-space revenue and capability narrative over a 1 year+ horizon

Why now: The timing is comparatively favorable: Voyager has dated within the recent evidence window evidence published May 26, 2026 for a $16.5M DARPA Phase 2 contract, May 29, 2026 defense/national security capability context, and June 4, 2026 current company capability context, all within the reviewed sources recent evidence window and relevant to a 1 year+ horizon

Caveats: Much of the evidence is supporting article context rather than direct positive rows. Some cited capability pages are company-provided materials. Ticker is absent in the required company entry even though external articles reference NYSE: VOYG; this output preserves the required ticker field from the input.

Thesis: Recent large Series B financing to build an AI-powered Earth mapping constellation supports a medium-strength long-horizon scaling opportunity.

Why now: Xoople closed a $130 million Series B on April 6, 2026/07 and articles say the capital is for building out its constellation; for a 1 year+ horizon, that financing can enable product and deployment progress, but the same dated coverage warns the market has historically been hard to monetize.

Caveats: Positive support is mostly supporting article context rather than positive evidence. Commercialization warning is article context, not a company-specific deterioration event. No direct customer, backlog, or launch milestone evidence is available.

Thesis: Aalyria Technologies appears attractive on reviewed sources evidence because it is directly included among awardees in U.S. Space Force Golden Dome contracts, a durable government-program signal that can matter over a 1 year+ horizon.

Why now: Current relevance is tied to the cited Space Force Golden Dome contract award context in article, though the reviewed sources omits the and representative article details.

Caveats: No article is supplied for the cited support article. Opportunity rests on a single contract-related rationale summary. Contract inclusion alone does not reveal contract size, economics, or conversion pace.

Thesis: Aavuus has the strongest recent opportunity setup in this screen because a dated article says it raised pre-seed funding and is building a global laser-based tracking network for debris tracking and collision avoidance in LEO, indicating financing plus product/infrastructure development in orbital safety and space domain awareness.

Why now: The opportunity is timely because the retained article is dated June 9, 2026 and describes a current financing and product build phase rather than stale background context. That said, recency comes from source date/article date, and evidence grounding is still article-level rather than direct fact/events., June 9, 2026

Caveats: Evidence is weak context and supporting article context, not direct structured positive event evidence. No explicit customer, contract, revenue, or regulatory milestone is cited. Same article appears in multiple rows and is not independent confirmation.

Thesis: The reviewed sources states Astroscale focuses on satellite repair, refueling, and debris removal, and partnered with SKY Perfect JSAT for on-orbit satellite services. That indicates strategic positioning in an emerging service layer with potentially durable 1 year+ relevance.

Why now: Why now is relatively constructive because a named partnership for on-orbit services can matter over a long strategic horizon, but exact timing and materiality cannot be validated from the reviewed sources because only membership rationale is visible.

Caveats: Membership rationale references article ID: but the reviewed sources provide no or article summary. Relation counts are present in support metadata, but relations are context-only unless separately policy-gated. No direct positive or negative evidence arrays are populated.

Thesis: Among the covered names, CesiumAstro has the clearest positive business context: an external article summary states it raised a $270M Series C round, bringing total funding to $655M, and provides communication systems for satellites, UAVs, launch vehicles, and other space or airborne platforms, suggesting better capitalization and broad platform relevance if that financing remains available to drive growth

Why now: There is no fresh catalyst inside the 90-day evidence window. The visible article was published on February 14, 2026 and is outside the cutoff date of March 29, 2026, so it is useful as background but weak for recency-sensitive ranking

Caveats: The visible positive article is outside the 90-day recent evidence window cutoff and was dropped from reviewed evidence. External supporting source context is allowed as evidence context but is not merged into primary data source.

Thesis: Constellr has the best supported long-horizon opportunity in this screen. A dated article published April 16, 2026 says constellr operates a proprietary satellite constellation for thermal intelligence, launched its first satellite in January 2025, and closed a €37 million Series A in February 2026, which together indicate product deployment plus fresh capital to scale over a 1 year+ horizon.

Why now: Why now is relatively strongest here because the retained evidence is within the 90-day recent evidence window and dated April 16, 2026, summarizing recent business-state milestones including a first satellite launch in January 2025 and a Series A closed in February 2026.

Caveats: Evidence is external article context, not a direct company filing or contract announcement.

Thesis: Eycore has a modest opportunity signal because a dated May 2026 article says it launched Eycore-1, its first Earth observation satellite equipped with the company's SAR technology. A first in-orbit asset can be strategically important over a 1 year+ horizon if it enables product validation and future commercial traction.

Why now: Why now is the dated first-satellite launch article from May 5, 2026, which is recent within the 90-day recent evidence window and relevant to a long-horizon de-risking story, though still early-stage.

Caveats: Evidence is supporting article context only, not a stronger structured positive event row. Single-article universe limits corroboration. No financing, customer, revenue, or performance follow-through evidence is provided.

Thesis: Reviewed evidence rationale says Guodian Gaoke received the first trial license for satellite IoT services and that Tianqi low-orbit IoT constellation Phase I is complete. A completed initial constellation phase plus first-trial-license status is one of the better long-horizon setup signals in this otherwise thin-evidence batch.

Why now: The why-now would be the reported trial license and completed Phase I constellation, but the reviewed sources does not provide the underlying article summary or date-specific evidence for stronger timing confidence.

Caveats: Phase2 membership rationale references: but no summary/evidence row is available to cite directly. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Score exceeds Beijing Guodian High-Tech slightly because rationale mentions both licensing and constellation completion.

Thesis: The reviewed sources membership rationale states Interlune won a $6.9M NASA contract for lunar resource development with a payload for lunar regolith volatiles and extraction demonstrations. For a 1 year+ horizon, that is a concrete external validation event that could support technology maturation and future lunar-resource positioning.

Why now: The key 'why now' is the cited NASA contract in article: but the reviewed sources does not include the article summary or, so exact date and latest status are not visible here.

Caveats: Opportunity case relies on membership rationale rather than included direct article evidence. A $6.9M contract is positive validation, but contract size alone may not be enough to de-risk a lunar-resource business. No negative evidence is provided, so risk mostly reflects execution uncertainty.

Thesis: Iridium has a moderate long-horizon opportunity case from current evidence that it operates a 66-satellite LEO constellation providing global mobile satellite communications, a durable strategic asset position if demand remains resilient.

Why now: The current support is an April 3, 2026 article-level overview of Iridium’s constellation and service footprint rather than a new event, so timing fit is only medium.

Caveats: Evidence is supporting article context, not a fresh contract or earnings-linked milestone.

Thesis: No negative thesis can be established because no direct negative evidence for Apparition Geoservices GmbH is available in the reviewed sources after recent evidence filtering.

Why now: No current business-state change or catalyst is visible. Although 6 articles were considered, coverage debug shows 0 articles after recent evidence window and 0 evidence after recent evidence window, while the membership review says the reviewed sources are only a broad European tech funding roundup without a direct company-specific description.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Mention count and article count do not increase conviction because no post-recent evidence window evidence are available. Review-status rationale says retrieval context is insufficient for membership.

Thesis: No negative thesis is supported because Arkeon has no direct negative evidence in the reviewed sources within the selected recent evidence window.

Why now: No company-specific timing signal is visible. Coverage debug shows zero post-recent evidence window articles and evidence, and the membership note says only a generic funding-roundup article was available without a company-specific description tying Arkeon to the scope.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article No direct event, fact, or negative development is available after recent evidence window. Low membership confidence is not directional evidence.

Thesis: No negative thesis can be formed because the reviewed sources includes no direct negative evidence for Ars Magna Semiconductors within the recent evidence window.

Why now: There is no visible long-horizon strategic catalyst in the usable evidence. Coverage debug shows zero post-recent evidence window articles and evidence, and the only cited support is a general tech funding roundup without a company-specific description linking the company to the scope.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article No direct positive or adverse operating evidence is available. Generic roundup context is weaker than company-specific evidence and is not directional proof.

Thesis: No negative thesis is supportable because the reviewed sources have no direct negative evidence for Augusta Labs after recent evidence filtering.

Why now: No current or durable catalyst can be identified from the reviewed sources. Coverage debug shows zero post-recent evidence window articles and evidence, and the membership note says the company is only present in a generic funding-roundup article without direct identification against the listed criteria.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Absence of risk evidence is not positive evidence. No direct company-specific facts or events are available.

Thesis: No negative thesis can be justified because no direct negative evidence for BeatpulseLabs is present in the reviewed sources within the recent evidence window.

Why now: There is no visible catalyst or deterioration signal. Coverage debug shows zero post-recent evidence window articles and evidence, and the only cited support is a generic funding-roundup article with no direct company-specific connection to the scope.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article No direct event or fact evidence is available after recent evidence window. Generic context should not be treated as directional proof.

Thesis: No negative/risk thesis can be supported because the reviewed sources contain no direct negative evidence for Bose Corporation after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 97 articles considered but 0 articles after recent evidence window and 0 evidence available after dedupe; despite broad article consideration, nothing survived the time/evidence filters for a 1 year+ thesis judgment.

Caveats: Phase-2 membership rationale says only a generic funding roundup was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

Thesis: No negative/risk thesis can be supported because the reviewed sources contain no direct negative evidence for Breaking Change after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 3 articles considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says the reviewed sources gives no meaningful company-specific evidence and references: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

Thesis: No negative thesis can be supported because there is no direct negative evidence for CameraMatics in the reviewed sources after recent evidence filtering.

Why now: No company-specific catalyst is visible despite 6 articles considered, because coverage debug shows 0 articles after recent evidence window and 0 evidence after recent evidence window. The membership note says the reviewed sources only includes CameraMatics in a generic funding roundup with no direct statement tying it to the scope.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Article count does not create conviction because no post-recent evidence window evidence are available. No direct positive or adverse company-specific event is available.

Thesis: No negative/risk thesis can be supported because the reviewed sources contain no direct negative evidence for Camphouse after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says only a generic roundup mention was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

Thesis: No negative/risk thesis can be supported because the reviewed sources contain no direct negative evidence for Capsa AI after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says only a generic funding roundup was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

Thesis: No negative/risk thesis can be supported because the reviewed sources contain no direct negative evidence for CardNexus after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says the reviewed sources does not provide direct company-specific evidence and references: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

Thesis: No negative/risk thesis can be supported because the reviewed sources contain no direct negative evidence for CeQur after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says only a generic funding roundup was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

Thesis: No negative thesis is supportable from retained reviewed sources evidence because no adverse events or facts are retained after recent evidence window.

Why now: No current catalyst is evidenced in the retained reviewed sources. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window.

Caveats: Phase-2 rationale references article, but the reviewed sources does not include the article summary or retained evidence. Supplier relevance to the space ecosystem does not by itself justify an opportunity score without current retained evidence. Recency is uncertain because the supporting substantive claims are not preserved in the recent evidence window evidence set.

Thesis: No negative thesis is supportable from retained reviewed sources evidence because no adverse direct evidence remains after recent evidence window.

Why now: There is no current why-now signal in the retained reviewed sources. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window.

Caveats: Phase-2 rationale references article: but the actual retained evidence is absent from these reviewed sources. The rationale itself frames IHI more as a beneficiary/customer than clearly as the core space operator, which weakens directional use even if the older article were available.

Thesis: No negative thesis is supportable from retained reviewed sources evidence because there are no direct negative evidence and no articles retained after the 90-day recent evidence window.

Why now: There is no current why-now signal in the reviewed evidence. Coverage debug shows zero article IDs after recent evidence window and zero evidence after dedupe/recent evidence window.

Caveats: Phase-2 rationale references article: but that article content is not provided here and no retained evidence remain after recent evidence window. Membership review status is not directional proof. Absence of evidence should not be interpreted as absence of business activity.

Thesis: No negative thesis is supportable from retained reviewed sources evidence because no adverse evidence remains after the 90-day recent evidence window.

Why now: No current why-now signal is available in the retained evidence. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window despite substantial historical article count.

Caveats: Phase-2 rationale references articles: and: but their content is not included here. Historical mention density is not conviction. Public listing/ticker presence does not create a directional thesis without retained evidence.

Thesis: No negative thesis is supportable from retained reviewed sources evidence because no negative events or facts are retained after recent evidence window.

Why now: No current why-now signal is available in the retained evidence. Coverage debug shows zero articles after recent evidence window and zero evidence after recent evidence window.

Caveats: Phase-2 rationale references article: but the underlying article details are not included here. A referenced letter of intent, without retained evidence details or timing, is insufficient for a 1 year+ directional ranking. Private-company status may limit visibility, but that is not itself a thesis.

Thesis: No negative thesis can be supported from the reviewed sources because there is no direct negative evidence available for Zone14 within the 90-day recent evidence window.

Why now: There is no current company-specific catalyst visible in the reviewed sources. Coverage debug shows zero articles after recent evidence window and zero evidence after recent evidence window for Zone14; the membership note says it appears only through a broad funding roundup and lacks company-specific evidence tied to the listed scope.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Evidence recent evidence review shows 0 kept rows after the March 29, 2026 cutoff. Company appears only in review status with low membership confidence, which is not directional evidence.